NCT07930260
Efficacy and Safety of Kabalin Cap.(Pregabalin) in Patients With Neuropathic Pain
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Proportion of participants with a ≥50% improvement in pain severity from baseline at Week 12
Timeframe: At Week 12 after enrollment
Sites
1 site in 1 country
- HK inno.NSeoul, South Korea